Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Vomiting 1Nausea 1Lung Neoplasms 1Esophageal Neoplasms 1

Interventions

Oxaliplatin 7Fluorouracil 7Paclitaxel 5Leucovorin 5pembrolizumab 4Trastuzumab 4Radiation 4Capecitabine 4tislelizumab 3Taxes 3Specimen Handling 3Nivolumab 3Carboplatin 3ulixertinib 2trastuzumab biosimilar HLX02 2patritumab deruxtecan 2Surgical Procedures, Operative 2Radiotherapy 2Pemetrexed 2PF-05280014 2Ontruzant 2Ogivri 2Irinotecan 2Exercise 2Docetaxel 2Cisplatin 2CT-P6 2zolbetuximab 1zimberelimab 1zanidatamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Palonosetron × 30 days × Clear all
NCT07617246 2026-06-01

The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
120 enrolled
GastrointestinalThoracic

Esophageal Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡